Z
Zining Wu
Researcher at GlaxoSmithKline
Publications - 3
Citations - 94
Zining Wu is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Histamine & Protein–protein interaction. The author has an hindex of 2, co-authored 3 publications receiving 52 citations.
Papers
More filters
Journal ArticleDOI
Structure-Activity and Structure-Conformation Relationships of Aryl Propionic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1/Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1/NRF2) Protein-Protein Interaction.
Tom D. Heightman,James F. Callahan,Elisabetta Chiarparin,Joseph E. Coyle,Charlotte Mary Griffiths-Jones,Ami S. Lakdawala,Rachel McMenamin,Paul N. Mortenson,David Norton,Torren M. Peakman,Sharna J. Rich,Caroline Richardson,William L. Rumsey,Yolanda Sanchez,Gordon Saxty,Henriëtte M. G. Willems,Lawrence Wolfe,Alison Jo-Anne Woolford,Zining Wu,Hongxing Yan,Jeffrey K. Kerns,T.G. Davies +21 more
TL;DR: A detailed account of the medicinal chemistry campaign leading to the KEAP1-NRF2 molecule is presented, which included exploration and optimization of protein-ligand interactions in three energetic "hot spots" identified by fragment screening.
Journal ArticleDOI
MrgX2 is a promiscuous receptor for basic peptides causing mast cell pseudo-allergic and anaphylactoid reactions.
Jak Grimes,Sapna Desai,Neil Charter,James Lodge,Rita Moita Santos,Albert Isidro-Llobet,Andrew M. Mason,Zining Wu,Lawrence Wolfe,Lakshmi Anantharaman,Andrew R. Green,Angela Bridges,Deidre Dalmas Wilk,Andrew J. Brown +13 more
TL;DR: The MrgX2 genes of rat, dog, minipig, pig, and Rhesus and cynomolgus monkey were identified by bioinformatic approaches and verified by their ability to mediate calcium mobilization in transfected cells in response to the classical Mrg X2 agonist, compound 48/80.
Journal ArticleDOI
Fragment-Guided Discovery of Pyrazole Carboxylic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2 Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction.
David Norton,William G. Bonnette,James F. Callahan,Maria Grazia Carr,Charlotte Mary Griffiths-Jones,Tom D. Heightman,Jeffrey K. Kerns,Hong Nie,Sharna J. Rich,Caroline Richardson,William L. Rumsey,Yolanda Sanchez,Marcel L. Verdonk,Henriëtte M. G. Willems,William E. Wixted,Lawrence Wolfe,Alison Jo-Anne Woolford,Zining Wu,T.G. Davies +18 more
TL;DR: In this paper, the authors used fragment-based drug discovery to develop a tool compound that directly disrupts the protein-protein interaction between NRF2 and KEAP1, which provided an alternative chemotype for lead optimization.